Literature DB >> 22738343

Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma.

Lucas L Cunha1, Elaine C Morari, Ana C T Guihen, Daniela Razolli, Renê Gerhard, Suely Nonogaki, Fernando A Soares, José Vassallo, Laura S Ward.   

Abstract

OBJECTIVE: Immune responses against differentiated thyroid carcinomas (DTC) have long been recognized. We aimed to investigate the role of immune cell infiltration in the progression of DTC.
DESIGN: We studied 398 patients - 253 with papillary and 13 with follicular thyroid cancers, as well as 132 with nonmalignant tissues. PATIENTS AND MEASUREMENTS: Immune cell infiltration was identified using CD3, CD4, CD8, CD20, CD68 and FoxP3 immunohistochemical markers. In addition, we assessed colocalization of CD4 and IL-17 to identify Th17 lymphocytic infiltration and colocalization of CD33 and CD11b to identify infiltration of myeloid-derived suppressor cells (MDSC).
RESULTS: Immune cells infiltrated malignant tissues more often than benign lesions. The presence of chronic lymphocytic thyroiditis (CLT) concurrent to DTC, CD68+, CD4+, CD8+, CD20+, FoxP3+ and Th17 lymphocytes but not MDSCs was associated with clinical and pathological features of lower tumour aggressiveness and a more favourable patient outcome. A log-rank test confirmed an association between concurrent CLT, tumour-associated macrophage infiltration, and CD8+ lymphocytes and an increased in disease-free survival, suggesting that evidence of these immune reactions is associated with a favourable prognosis.
CONCLUSION: Our data suggest that the tumour or peri-tumoural microenvironment may act to modify the observed pattern of immune response. Immune cell infiltration and the presence of concurrent CLT helped characterize specific tumour histotypes associated with favourable prognostic features.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22738343     DOI: 10.1111/j.1365-2265.2012.04482.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  50 in total

1.  Papillary thyroid carcinoma behavior: clues in the tumor microenvironment.

Authors:  Kensey Bergdorf; Donna C Ferguson; Mitra Mehrad; Kim Ely; Thomas Stricker; Vivian L Weiss
Journal:  Endocr Relat Cancer       Date:  2019-06       Impact factor: 5.678

2.  The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma.

Authors:  Yun Zhang; Jiaqi Dai; Tingting Wu; Nailin Yang; Zhiqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-12       Impact factor: 4.553

Review 3.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

4.  Positive effect of RORγt on the prognosis of thyroid papillary carcinoma patients combined with Hashimoto's thyroiditis.

Authors:  Rong Zeng; Yi Lyu; Guoqiao Zhang; Tao Shou; Kai Wang; Heng Niu; Xinmin Yan
Journal:  Am J Transl Res       Date:  2018-10-15       Impact factor: 4.060

5.  Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes.

Authors:  T Pilli; P Toti; R Occhini; M G Castagna; S Cantara; M Caselli; S Cardinale; L Barbagli; F Pacini
Journal:  J Endocrinol Invest       Date:  2017-12-11       Impact factor: 4.256

Review 6.  The correlations between IL-17 vs. Th17 cells and cancer patient survival: a systematic review.

Authors:  Simone Punt; Jessica M Langenhoff; H Putter; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova
Journal:  Oncoimmunology       Date:  2015-03-06       Impact factor: 8.110

7.  Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer.

Authors:  Simone Punt; Gert Jan Fleuren; Eva Kritikou; Erik Lubberts; J Baptist Trimbos; Ekaterina S Jordanova; Arko Gorter
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

8.  MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.

Authors:  Trevor E Angell; Melissa G Lechner; Julie K Jang; Jonathan S LoPresti; Alan L Epstein
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

9.  Thyroid autoimmunity: is really associated with papillary thyroid carcinoma?

Authors:  Alev Selek; Berrin Cetinarslan; Ilhan Tarkun; Zeynep Canturk; Berna Ustuner; Zeynep Akyay
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-08       Impact factor: 2.503

10.  Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer.

Authors:  Ylia Salazar; Xiang Zheng; David Brunn; Hartmann Raifer; Felix Picard; Yajuan Zhang; Hauke Winter; Stefan Guenther; Andreas Weigert; Benno Weigmann; Laure Dumoutier; Jean-Christophe Renauld; Ari Waisman; Anja Schmall; Amanda Tufman; Ludger Fink; Bernhard Brüne; Tobias Bopp; Friedrich Grimminger; Werner Seeger; Soni Savai Pullamsetti; Magdalena Huber; Rajkumar Savai
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.